Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

317.37 +8.47 (+2.74%)
Streaming Delayed Price Updated: 1:59 PM EDT, May 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 134,439
Open 317.01
Bid (Size) 316.00 (2)
Ask (Size) 317.70 (2)
Prev. Close 308.90
Today's Range 310.00 - 318.23
52wk Range 249.50 - 356.78
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Golden Cross Appears Before argenx Investors
If history is any guide, there may be good fortune ahead for shares of argenx (NASDAQ:ARGX). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the... 
Via Benzinga
Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study
 
Via Benzinga

Performance

YTD
-9.60%
-9.60%
1 Month
+0.13%
+0.13%
3 Month
+11.94%
+11.94%
6 Month
+5.37%
+5.37%
1 Year
+14.31%
+14.31%

More News

Read More
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Recap: argenx Q1 Earnings
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022
Via Benzinga
Argenx's Vyvgart Long-Term Treatment Shows Improved gMG Disease Scores
Via Benzinga
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
Via Benzinga
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
From argenx SE
Via Business Wire
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale
Via Benzinga
Recap: argenx Q4 Earnings
Via Benzinga
argenx's Earnings: A Preview
Via Benzinga
Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx
Via Benzinga
Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
Via Benzinga
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
From argenx SE
Via Business Wire
What 8 Analyst Ratings Have To Say About argenx
Via Benzinga
What 8 Analyst Ratings Have To Say About argenx
Via Benzinga
What 8 Analyst Ratings Have To Say About argenx
Via Benzinga
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug
Via Benzinga
argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis
From argenx
Via Business Wire
argenx Highlights Strategic Priorities for 2022
From argenx
Via Business Wire
Earnings Scheduled For March 3, 2022
Via Benzinga
65 Biggest Movers From Yesterday
Via Benzinga
38 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Argenx's Vyvgart Wins FDA Approval For Autoimmune, Neuromuscular Disease
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.